Vanda Pharmaceuticals (VNDA) Deferred Taxes (2010 - 2025)

Vanda Pharmaceuticals has disclosed Deferred Taxes across 8 years of filings, most recently posting $103.2 million for Q4 2025.

• Deferred Taxes for Q4 2025 came in at $103.2 million, up 5491.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.2 million (up 735.93% YoY), and the FY2025 annual result was $81.4 million, up 1356.45% from the prior year.
• Deferred Taxes came in at $103.2 million for Q4 2025 at Vanda Pharmaceuticals, up from -$6.0 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $103.2 million in Q4 2025 to a low of -$8.0 million in Q2 2025.
• The 5-year median for Deferred Taxes is $85500.0 (2022), against an average of $4.1 million.
• Peak annual rise in Deferred Taxes reached 5491.12% in 2025, while the deepest fall reached 3069.51% in 2025.
• Vanda Pharmaceuticals' Deferred Taxes stood at $1.3 million in 2021, then plunged by 68.24% to $417000.0 in 2022, then tumbled by 1894.72% to -$7.5 million in 2023, then soared by 74.43% to -$1.9 million in 2024, then surged by 5491.12% to $103.2 million in 2025.
• The last three Deferred Taxes figures came in at $103.2 million (Q4 2025), -$6.0 million (Q3 2025), and -$8.0 million (Q2 2025), per Business Quant data.